Elevation of the tumor mutational burden, enhanced antigen presentation and cellular immunity, and increased PD-L1 expression, are all correlated with the presence of ARID1A and ARID1B mutations; suggesting that mutated ARID1A and ARID1B could serve as novel biomarkers to predict sensitivity and prognosis to ICB in advanced NSCLC patients (55). This evidence concerns the gene CD274 and neoplasm.